Lenalidomide
- Generic Name
- Lenalidomide
- Indication
⑴主要用于具有5q缺失细胞遗传学异常的骨髓增生异常综合征所致的输血依赖性贫血患者的治疗。⑵与地塞米松合用治疗已经接受过至少一种疗法的多发性骨髓瘤（套细胞淋巴瘤（MCL））患者。
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 176
- Registration Number
- NCT01947309
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳Xiangya Hospital Central-South University, Changsha, China
🇨🇳Shanghai Changzhen Hospital, Shanghai, China
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT01752075
- Locations
- 🇨🇳
NTUH, Taipei, Taiwan
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Duke University
- Target Recruit Count
- 17
- Registration Number
- NCT01729338
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 42
- Registration Number
- NCT01621672
- Locations
- 🇺🇸
University of Arkansas for Medical Science-MIRT, Little Rock, Arkansas, United States
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT01572480
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer
- Conditions
- Pancreatic Carcinoma MetastaticPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Maria Liljefors
- Target Recruit Count
- 34
- Registration Number
- NCT01547260
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Solna, Sweden
Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT01450215
- Locations
- 🇸🇪
Karolinska Institute, Stockholm, Sweden
🇸🇪Karolinska Inst., Stockholm, Sweden
Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
- Conditions
- Chronic Myelomonocytic Leukemia
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 30
- Registration Number
- NCT01368757
- Locations
- 🇦🇹
Krankenhaus d. Barmherzigen Schwestern Linz, Interne I, Linz, Oberösterreich, Austria
🇦🇹Klinikum Wels-Grieskirchen GmbH, IV. Interne Abteilung, Wels, Oberösterreich, Austria
🇦🇹AKH Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie, Linz, Oberösterreich, Austria
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 18
- Registration Number
- NCT01241734
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
- Conditions
- Small Lymphocytic LymphomaChronic Lymphocytic Leukemia(CLL)
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 5
- Registration Number
- NCT01241786
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.